Most Ketamine users are unaware that even occasional usage can cause untreatable ulcerative cystitis, a.k.a. Ketamine Bladder Syndrome. Ketamine thins the urothelium while increasing the collagen to smooth muscle ratio and exacerbating interstitial fibrosis. The syndrome is untreatable and causes serious problems down the line. One promising rat study from 2015 shows that EGCG (epigallocatechin gallate) extracted fro…
Amygdala connectivity predicts ketamine treatment response
21–30 of 47 posts
Re: Amygdala connectivity predicts ketamine treatment response
#22Earlier quoted context omitted.
This sounds really promising, but one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). When heroin was first discovered, it was hailed as a wonder-drug, and it was also considered an effective treatment for severe depression. However, after some time, people realized that its addictive properties and high range of potential tolerance make it backfire pretty badly after a certa…
From what I've heard ketamine is already (ab)used as a recreational drug since decades back and does have addiction risk. Not addiction risk anything like heroin though, and the trips are apparently mostly unpleasant. Ketamine in its present form is decidedly not ideal for depression treatment, but probably a tradeoff often worth considering compared to the risks of severe and enduring depression. Amine neurotransmit…
Re: Amygdala connectivity predicts ketamine treatment response
#23Most Ketamine users are unaware that even occasional usage can cause untreatable ulcerative cystitis, a.k.a. Ketamine Bladder Syndrome. Ketamine thins the urothelium while increasing the collagen to smooth muscle ratio and exacerbating interstitial fibrosis. The syndrome is untreatable and causes serious problems down the line. One promising rat study from 2015 shows that EGCG (epigallocatechin gallate) extracted fro…
Thanks for bringing this up. It's super important. And also makes me why other drugs in this class (dissociatives) aren't being looked more aggressively. Dextromethorphan -- in common cough syrup -- is one example. It has other side effects (nausea, etc.) but doesn't have the bladder destructive issues associated with ketamine.
The fact that they're both dissociatives doesn't mean they're substitutable in any given context.
Dextromethorphan is a much riskier drug overall than ketamine, in almost every measurable way. It's very easy to overdose on dextromethorphan, to the point where people routinely do it by accident while self-medicating for a cough. By contrast, it's actually quite difficult to overdose on ketamine - the LD50 is quite high, and a person would likely incapacitate themselves halfway through and be unable to finish.
They also have dramatically different effects - there are actually very few contexts in which both could be considered an acceptable choice for a given goal.
The bladder issues with ketamine are only documented for chronic heavy users. There's no clinical evidence of it for one-time use, and given the extensive use of ketamine in controlled settings for several decades, the absence of evidence is (in this case) strong evidence of absence.
Re: Amygdala connectivity predicts ketamine treatment response
#24Earlier quoted context omitted.
Thanks for bringing this up. It's super important. And also makes me why other drugs in this class (dissociatives) aren't being looked more aggressively. Dextromethorphan -- in common cough syrup -- is one example. It has other side effects (nausea, etc.) but doesn't have the bladder destructive issues associated with ketamine.
> Thanks for bringing this up. It's super important. And also makes me why other drugs in this class (dissociatives) aren't being looked more aggressively. Dextromethorphan -- in common cough syrup -- is one example. It has other side effects (nausea, etc.) but doesn't have the bladder destructive issues associated with ketamine The fact that they're both dissociatives doesn't mean they're substitutable in any given…
On other hand I've been in, and had friends in, so-called "k-holes" because of doses of ketamine that were too high and the experience was ... awful. Imagine thinking you're dead, but you're still conscious.
Both are NMDA antagonists. Both provide emotional and physical dissociation. They are in the a similar class of experiences.
Psychotherapeutic doses of ketamine are not one-time. At least not from the reading I've been doing. They have been found to be more effective done over several sessions. I honestly worry about the potential for bladder damage because it has not been studied well and also this kind of treatment is something we're looking into for a loved one
Re: Amygdala connectivity predicts ketamine treatment response
#25Earlier quoted context omitted.
This sounds really promising, but one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). When heroin was first discovered, it was hailed as a wonder-drug, and it was also considered an effective treatment for severe depression. However, after some time, people realized that its addictive properties and high range of potential tolerance make it backfire pretty badly after a certa…
Good question. Ketamine has been a party drug for quite a while now, and as far as I know, hasn't been shown to be particularly dependency-inducing, though low-dose ketamine over the long term might be ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236511/ ) Also, as far as I know, ketamine treatment isn't intended as an ongoing medication, like an SSRI, but as a treatment for acute episodes of depression. I might b…
At Lumin Health, we treat about 80% of our patients with esketamine, and the rest with ketamine (generally only if they don't meet esketamine criteria). After the initial course, patients tend to find a good balance of ongoing care that helps treat their particular depression / depressive symptoms. This happens less with ketamine since it tends to be prohibitively expensive to continue care (upwards of $1k/month).
Re: Amygdala connectivity predicts ketamine treatment response
#26Earlier quoted context omitted.
This sounds really promising, but one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). When heroin was first discovered, it was hailed as a wonder-drug, and it was also considered an effective treatment for severe depression. However, after some time, people realized that its addictive properties and high range of potential tolerance make it backfire pretty badly after a certa…
> one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). The fact that two drugs both can be used as an anesthetic doesn't tell you very much besides that, especially when comparing across different drug classes. For example, cocaine and novocaine are both anesthetics that belong to the same drug class, and yet they have radically different risk profiles, despite both being comm…
People on these type of drugs long term end up with severe memory issues, fogfy brained all the time, and if its ketamine add in a completely obliterated bladder.
I dont think this is an idea that can be dismissed trivially as a fallacy.
Re: Amygdala connectivity predicts ketamine treatment response
#27Re: Amygdala connectivity predicts ketamine treatment response
#28Earlier quoted context omitted.
Good question. Ketamine has been a party drug for quite a while now, and as far as I know, hasn't been shown to be particularly dependency-inducing, though low-dose ketamine over the long term might be ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236511/ ) Also, as far as I know, ketamine treatment isn't intended as an ongoing medication, like an SSRI, but as a treatment for acute episodes of depression. I might b…
The WebMD article is referencing esketamine, also known as Spravato, which is an FDA authorized form of ketamine. It's generally indicated for longer-term use in patients with Treatment Resistant Depression (TRD), and has really good results on par with ketamine (IV or intramuscular). At Lumin Health, we treat about 80% of our patients with esketamine, and the rest with ketamine (generally only if they don't meet esk…
Re: Amygdala connectivity predicts ketamine treatment response
#29I dont understand why we arent looking into methoxetamine over ketamine. Or any of the derivatives with a stronger dose-response curve. DCK, O-PCE, etc. These all have similar chemical and psychoactive properties and the doses are orders of magnitude smaller ergo they dont completepy fuck your bladder up.
Seems like we are.
https://scholar.google.com/scholar?start=10&q=methoxetamine+...
Re: Amygdala connectivity predicts ketamine treatment response
#30Earlier quoted context omitted.
This sounds really promising, but one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). When heroin was first discovered, it was hailed as a wonder-drug, and it was also considered an effective treatment for severe depression. However, after some time, people realized that its addictive properties and high range of potential tolerance make it backfire pretty badly after a certa…
> one thing that worries me is that ketamine is a sort-of painkiller (dissociative anesthetic). The fact that two drugs both can be used as an anesthetic doesn't tell you very much besides that, especially when comparing across different drug classes. For example, cocaine and novocaine are both anesthetics that belong to the same drug class, and yet they have radically different risk profiles, despite both being comm…
Sure, but it's also a fallacy to assume that nothing bad can happen in the long-term just because it appears promising in the short-term. I wasn't saying it's gonna happen the same exact way as it did with heroin (of course it won't, it's not an opiate), I was just making an example of a drug that happened to appear benign and promising, but have serious unforeseen consequences in the long term.